Purple Biotech Ltd (KTOV) - Net Assets
Based on the latest financial reports, Purple Biotech Ltd (KTOV) has net assets worth ILA56.15 Million ILA (≈ $150.52K USD) as of June 2020. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA85.78 Million ≈ $229.98K USD) and total liabilities (ILA29.64 Million ≈ $79.46K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check KTOV asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ILA56.15 Million |
| % of Total Assets | 65.45% |
| Annual Growth Rate | 0.13% |
| 5-Year Change | 15.17% |
| 10-Year Change | N/A |
| Growth Volatility | 345.37 |
Purple Biotech Ltd - Net Assets Trend (2009–2019)
This chart illustrates how Purple Biotech Ltd's net assets have evolved over time, based on quarterly financial data. Also explore KTOV asset base for the complete picture of this company's asset base.
Annual Net Assets for Purple Biotech Ltd (2009–2019)
The table below shows the annual net assets of Purple Biotech Ltd from 2009 to 2019. For live valuation and market cap data, see KTOV market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2019-12-31 | ILA10.86 Million ≈ $29.11K |
-1.32% |
| 2018-12-31 | ILA11.00 Million ≈ $29.50K |
+28.06% |
| 2017-12-31 | ILA8.59 Million ≈ $23.04K |
-35.80% |
| 2016-12-31 | ILA13.38 Million ≈ $35.88K |
+41.96% |
| 2015-12-31 | ILA9.43 Million ≈ $25.28K |
+1007.99% |
| 2014-12-31 | ILA851.00K ≈ $2.28K |
+189.96% |
| 2013-12-31 | ILA-946.00K ≈ $-2.54K |
-127.28% |
| 2011-12-31 | ILA3.47 Million ≈ $9.30K |
-43.58% |
| 2010-12-31 | ILA6.15 Million ≈ $16.48K |
-42.63% |
| 2009-12-31 | ILA10.71 Million ≈ $28.72K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Purple Biotech Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4952200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2019)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ILA59.94 Million | 575.21% |
| Total Equity | ILA10.42 Million | 100.00% |
Purple Biotech Ltd Competitors by Market Cap
The table below lists competitors of Purple Biotech Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Digital 9 Infrastructure PLC
LSE:DGI9
|
$463.17K |
|
Nuvve Holding Corp
NASDAQ:NVVE
|
$464.01K |
|
MOVEBYBIKE EUROPE AB
F:6ZR
|
$464.77K |
|
Christie Group plc
LSE:CTG
|
$467.74K |
|
SECITS Holding AB (publ)
ST:SECI
|
$458.10K |
|
Tian Ruixiang Holdings Ltd
NASDAQ:TIRX
|
$458.06K |
|
Kermode Resources Ltd
V:KLM
|
$456.21K |
|
RT Minerals Corp
V:RTM
|
$456.08K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Purple Biotech Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2018 to 2019, total equity changed from 10,523,000 to 10,421,000, a change of -102,000 (-1.0%).
- Net loss of 5,850,000 reduced equity.
- Other factors increased equity by 5,748,000.
Equity Change Factors (2018 to 2019)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ILA-5.85 Million | -56.14% |
| Other Changes | ILA5.75 Million | +55.16% |
| Total Change | ILA- | -0.97% |
Book Value vs Market Value Analysis
This analysis compares Purple Biotech Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently Purple Biotech Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -56.14%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -585.00%
- • Asset Turnover: 0.07x
- • Equity Multiplier: 1.41x
- Recent ROE (-56.14%) is above the historical average (-146.52%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | ILA-2.53 Million |
| 2014 | -617.16% | 0.00% | 0.00x | 2.07x | ILA-5.34 Million |
| 2015 | -44.56% | 0.00% | 0.00x | 1.15x | ILA-5.14 Million |
| 2016 | -90.59% | 0.00% | 0.00x | 1.11x | ILA-13.46 Million |
| 2017 | -167.81% | -12272.00% | 0.01x | 1.94x | ILA-13.00 Million |
| 2018 | -49.42% | -520.00% | 0.07x | 1.40x | ILA-6.25 Million |
| 2019 | -56.14% | -585.00% | 0.07x | 1.41x | ILA-6.89 Million |
Industry Comparison
This section compares Purple Biotech Ltd's net assets metrics with peer companies in the Biotechnology & Medical Research industry.
Industry Context
- Industry: Biotechnology & Medical Research
- Average net assets among peers: $36,617,000
- Average return on equity (ROE) among peers: -74.95%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Purple Biotech Ltd (KTOV) | ILA56.15 Million | 0.00% | 0.53x | $461.41K |
| Hadasit Bio (HDST) | $35.08 Million | -88.98% | 0.11x | $2.17 Million |
| Pluristem (PSTI) | $38.16 Million | -60.92% | 0.20x | $91.49 Million |
About Purple Biotech Ltd
Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension i… Read more